Genzyme's FDA issues remain unresolved

Genzyme suffered a surprising regulatory setback in plans to expand production of its treatment for Pompe disease, after the company had issued an optimistic outlook based in part on its prediction that the expansion would be cleared. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.